A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer – first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24)

Steger, GG, Greil, R, Jakesz, R, Lang, A, Mlineritsch, B, Melbinger-Zeinitzer, E, Martin, C, Samonigg, H, Kubista, E, Gnant, M